|
Name |
4H-Pyran-4-one
|
Molecular Formula | C5H4O2 | |
IUPAC Name* |
pyran-4-one
|
|
SMILES |
C1=COC=CC1=O
|
|
InChI |
InChI=1S/C5H4O2/c6-5-1-3-7-4-2-5/h1-4H
|
|
InChIKey |
CVQUWLDCFXOXEN-UHFFFAOYSA-N
|
|
Synonyms |
4H-PYRAN-4-ONE; 108-97-4; Pyran-4-one; gamma-Pyrone; 4-Pyrone; .gamma.-Pyrone; 4-oxo-4H-pyran; UJ7X07IM7Z; 4-Pyranone; UNII-UJ7X07IM7Z; EINECS 203-634-8; 4-oxo-1H-pyran; 4H-pyran-4-on; 4H-Pyran, 4-oxo-; CHEBI:37966; 4H-Pyran-4-one, >=98%; DTXSID20148352; ZINC2041085; MFCD00006576; AKOS016008736; AS-56532; DB-040854; CS-0108723; FT-0626622; EN300-49123; J-002217; Q3411301; Z586248016
|
|
CAS | 108-97-4 | |
PubChem CID | 7968 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 96.08 | ALogp: | 0.1 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 7 | QED Weighted: | 0.483 |
Caco-2 Permeability: | -4.269 | MDCK Permeability: | 0.00003100 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.044 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.947 | Plasma Protein Binding (PPB): | 83.06% |
Volume Distribution (VD): | 1.637 | Fu: | 39.16% |
CYP1A2-inhibitor: | 0.724 | CYP1A2-substrate: | 0.382 |
CYP2C19-inhibitor: | 0.161 | CYP2C19-substrate: | 0.141 |
CYP2C9-inhibitor: | 0.018 | CYP2C9-substrate: | 0.097 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.51 |
CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.191 |
Clearance (CL): | 8.795 | Half-life (T1/2): | 0.757 |
hERG Blockers: | 0.071 | Human Hepatotoxicity (H-HT): | 0.122 |
Drug-inuced Liver Injury (DILI): | 0.402 | AMES Toxicity: | 0.117 |
Rat Oral Acute Toxicity: | 0.866 | Maximum Recommended Daily Dose: | 0.033 |
Skin Sensitization: | 0.182 | Carcinogencity: | 0.941 |
Eye Corrosion: | 0.935 | Eye Irritation: | 0.993 |
Respiratory Toxicity: | 0.972 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000678 | 0.333 | D0X9RY | 0.216 | ||||
ENC005617 | 0.271 | D08ZEB | 0.214 | ||||
ENC000675 | 0.268 | D0D5GG | 0.213 | ||||
ENC000681 | 0.256 | D08YIN | 0.212 | ||||
ENC000190 | 0.250 | D07HBX | 0.205 | ||||
ENC000025 | 0.238 | D09XQF | 0.200 | ||||
ENC000038 | 0.238 | D08SKH | 0.200 | ||||
ENC000480 | 0.235 | D03UOT | 0.200 | ||||
ENC000162 | 0.235 | D05OIS | 0.194 | ||||
ENC000012 | 0.229 | D03GET | 0.191 |